Overview of Products and Services

StaRT-PCR Biomarker Kits

StaRT-PCR Assays Available

New Gene Assays Development

Quality Assurance for StaRT-PCR Assays
StaRT-PCR gene assay products are designed and developed under the FDA Good Laboratory Practice (GLP) regulations (21 CFR Part 58) and in compliance with Gene Express' defined and tested SOPs (Standardized Operation Procedures). The 29-step assay development process is highly quality controlled (QC) and quality assurance (QA). (See QC/QA White Paper)

StaRT-PCR assays are precisely designed, with controlled manufacturing of reagents and rigorous assay protocols which yield high quality StaRT-PCR multi-gene Transcript Abundance Measurements. This high quality is the result of rigorous manufacturing practices for the component reagents and strict adherence to Standard Operating Procedures (SOPs) in our production facility and the SEM Center. This requires the employment of stringent quality control (QC) and quality assurance (QA) measures throughout the development process. The quality control and quality assurance processes involved in the design and manufacture of StaRT-PCR assays and reagents are described in a technical white paper.

The reagents used in StaRT-PCR are manufactured with stringent quality control and quality assurance. The end result is the highest quality transcript abundance data in the industry today. The standardized data that is obtained is not only critical for application to diagnostics and drug development but will also enhance our understanding of various disease processes.

The stringent quality control (QC) and quality assurance (QA) measures are listed in the table below:

QA/QC steps for StaRT-PCR*** reagents
Reagent QC/QA Test Acceptable Specifications
Individual primer pairs Correct sequence and amount COA from manufacturer
Specificity BLAST search of primer sequence verified to be 100% correct. No hit with non-specific targets.
Correct amplimer size verified for both internal standard and native template
Primer sequences of internal standard verified to be 100% correct by sequence analysis
Lack of SNP interference Primer sequences devoid of known SNPs
Discrimination of alternative transcripts Primers designed to allow for differentiation of alternative transcripts
Primer stock solutions PCR with no template Free from Internal Standard or native template contamination
Primer stock solutions/IS* PCR with IS only Correct size IS amplimer
No interfering products
Internal Standard* Concentration of each internal standard determined by standard method Each internal standard quantified using the Hoechst dye method with a calf thymus DNA standard
Primer stock solutions/IS*/SMIS** Lower limit of detection Amplimer from 60 molecules or less of template
SMIS PCR with SMIS� only Correct size IS for each assay
No native template contamination
Functional test: StaRT-PCR� with Universal Human RNA Correct native template and Internal Standard amplimer produced, assay characteristics acceptable
Pipettes, hoods, fluorometer, thermocycler blocks all on a routine calibration/maintenance schedule
* Internal Standard
** Standardized Mixtures of Internal Standards (SMIS).
*** "StaRT-PCR" - Standardized (Sta), Reverse Transcriptase (RT), Polymerase Chain Reaction (PCR) - PCR is an enzymatic process to increase the number of copies of DNA for easier detection.